Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

05/26/2026, 1:00 PM • GlobeNewswire

BioMarin Reveals Dwarfism Study Data, Stock Soars

BioMarin Pharmaceutical's Phase 3 CANOPY-HCH-3 study for VOXZOGO demonstrated a statistically significant 2.33 cm/year increase in annualized growth velocity for hypochondroplasia treatment, meeting its primary endpoint. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026. The stock surged 8.05% to $54.24 on the positive results, with analysts maintaining a Buy rating and average price target of $87.47.

05/21/2026, 2:11 PM • Benzinga

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

CIBRA Capital significantly increased its stake in Amicus Therapeutics by 1.48 million shares worth $21.17 million during Q1 2026, making it the fund's largest position at 11.78% of AUM. The investment is a merger arbitrage bet on BioMarin Pharmaceutical's $14.50 per share acquisition offer, with potential $0.20 per share profit if the deal completes as expected.

04/25/2026, 11:13 AM • The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

03/20/2026, 12:07 PM • The Motley Fool

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1.054 million shares of Nuvalent (NUVL) for approximately $103.93 million in Q4, reducing its position to less than 1% of assets under management. Despite the sale, Nuvalent shares have rallied nearly 30% over the past year and the company is well-positioned financially with $1.4 billion in cash, awaiting potential FDA decisions on its cancer drug candidates later in 2026.

03/16/2026, 8:00 PM • The Motley Fool

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

03/10/2026, 2:49 PM • Benzinga

Skeletal Dysplasia Market - Global Forecast 2026-2032: $5.37 Bn Opportunities Driven by Advancing Diagnostic Precision, Integrated Therapies, Evidence Generation, and Equitable Access

The global skeletal dysplasia market is projected to grow from $3.48 billion in 2026 to $5.37 billion by 2032, with a CAGR of 7.42%. Growth is driven by advances in molecular diagnostics, biologic and enzyme replacement therapies, and improved multidisciplinary care pathways. Key opportunities include diagnostic precision, integrated therapies, evidence generation, and equitable access across regional markets.

03/05/2026, 4:51 AM • GlobeNewswire

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

02/12/2026, 12:44 PM • Benzinga

10 Magnificent Stocks That Can Make You Richer in 2026

The article identifies 10 stocks positioned to deliver strong returns in 2026 across growth, value, and income categories. These include payment processor Visa, adtech firm The Trade Desk, social media giant Meta, healthcare conglomerate UnitedHealth Group, satellite radio operator Sirius XM, drug developer BioMarin Pharmaceutical, utility NextEra Energy, cybersecurity provider Okta, water utility York Water, and auto parts retailer O'Reilly Automotive. Each stock is highlighted for competitive advantages, attractive valuations, or strong historical performance.

01/05/2026, 4:06 AM • The Motley Fool

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED)

Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.

12/24/2025, 9:14 AM • Benzinga

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Wednesday?

Wall Street traded modestly higher Wednesday with the S&P 500 up 0.4% near 6,900, buoyed by stronger-than-expected U.S. GDP growth of 4.3%. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals extended historic rallies, with silver breaking above $70 (up 140% YTD), gold reaching record highs, and platinum surging 5.5% to 2008 levels.

12/23/2025, 1:18 PM • Benzinga

What's Going On With BioMarin Stock On Tuesday?

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion on Friday. The acquisition is expected to accelerate revenue growth and be accretive to earnings within 12 months. Analysts view the deal favorably, with Truist Securities raising its price target from $80 to $100. The acquisition adds two revenue-generating rare disease therapies and diversifies BioMarin's portfolio, though longer-term technical trends remain under pressure.

12/23/2025, 1:05 PM • Benzinga

Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight

The pulmonary emphysema market is projected to grow steadily by 2034, driven by increasing COPD prevalence, an aging population, and advances in therapeutic treatments. Emerging therapies and innovative drugs are expected to transform the market landscape.

11/03/2025, 1:00 PM • GlobeNewswire

AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034

The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.

10/07/2025, 11:00 AM • GlobeNewswire

Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth

Global Pompe disease treatment market is growing steadily, driven by enzyme replacement therapies and improved diagnostic technologies, with ongoing research into gene therapy and small molecule treatments promising more efficient solutions.

10/01/2025, 5:48 AM • GlobeNewswire